Compare Diamondback Energy Inc (FANG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Novartis AG — how do they compare? Diamondback Energy Inc trades at $200.41 (market cap $56.48B), while Novartis AG trades at $152.87 (market cap $295.37B). The key difference: Novartis AG is far larger — about 5.2× Diamondback Energy Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| FANG | NVS | |
|---|---|---|
Market Cap | $56.48B | $295.37B |
Sector | Energy | Health |
52-Week High | $213.69 | $168.62 |
52-Week Low | $134.53 | $119.31 |
Enterprise Value | $68.63B | $336.69B |
Dividend Yield | 2.18% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $198.97, up 5.81% with strong Q2 2026 earnings beating estimates. Technical indicators show bullish momentum with support at $193 and resistance at $202. Revenue grew to $14.93B in 2025, though profit margins compressed to 11.14%. Analyst consensus is strongly bullish with a $236.63 price target and 90% buy ratings.
FANG offers growth potential through production increases and debt reduction, supported by elevated oil prices. Risks include commodity price volatility and margin pressure from rising costs. The stock trades at a premium P/E of 38.42 but remains attractive given operational efficiency gains and institutional accumulation.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
